On August 4, WUXI XDC rose 5.66% in regular trading, trading at 54.0 HKD/share, with turnover of approximately 59.54 million HKD. The rally was driven by a broad-based CXO sector surge combined with rising expectations ahead of the company's interim results disclosure scheduled for August 24.

The CXO sector saw significant collective strength on the day, with peer WUXI APPTEC surging 11.6%, PHARMARON gaining 6.34%, and GENSCRIPT BIO rising 4.48%, reflecting pronounced sector linkage effects. As the global leader in ADC CRDMO services with an estimated 24% market share, WUXI XDC is positioned to benefit from a recovery in global biotech financing and sustained strong ADC R&D investment, prompting early fund positioning ahead of mid-year results.

Supporting the bullish sentiment, CLSA recently raised its target price to 82.6 HKD while maintaining an Outperform rating, forecasting revenue growth of 33% for the current year and adjusted net profit growth exceeding guidance. Daiwa also initiated coverage with a Buy rating and a 78 HKD target, naming it a top CXO sector pick given its full-chain CRDMO capabilities and expanding global ADC outsourcing market share.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)